About US
Contact us
-
FDA warning slams drugmaker that made teething tablets containing belladonnaAn FDA warning letter has slammed the New Jersey CMO that produced belladonna-treated teething products sold by CVS thatthe agency last year warnedmight cause hallucinations and seizures in infants.2017/7/21
-
Senators lay into Sanofi for Zika vaccine deal, call for public hearingSanofi’s commitment to limit price hikes hasn’t won over sixU.S. senatorswho are railing on the drugmaker for a Zika dustup that’s gained considerable attention since vaccine licensing plans were anno2017/7/21
-
US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitisThe US Food and Drug Administration (FDA) has accepted for filing Pfizer’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate), an investigational oral solution to treat adult p2017/7/20
-
Glenmark secures UK MHRA approval for anti-malarial medicationGlenmark Pharmaceuticals Europe (Glenmark)has securedfinal approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Maloff Protect, its range ofatovaquone / proguanil film-c2017/7/20
-
Synlogic completes first phase in ongoing R&D collaboration with AbbVieUS-based pharmaceutical firm Synlogic has met the first discovery milestone in its ongoing research and development (R&D) collaboration with AbbVie. In the completed first discovery phase, Synlog2017/7/19
-
Roivant forms new subsidiary to develop urology therapiesHealthcare firm Roivant Sciences has formed a new subsidiary known as ‘Urovant Sciences’ to develop new therapies for addressing urologic conditions. Urovant has licensed global rights, except in cer2017/7/19
-
Lundbeck secures rights to IBC's research for Alzheimer's treatmentDanish pharmaceutical company Lundbeck has signed an agreement to secure the rights of biotech firm ImmunoBrain Checkpoint’s (IBC) breakthrough research in Alzheimer's disease treatment. The research2017/7/18
-
Merck and F-star to develop five bispecific immuno-oncology antibodiesGerman science and technology firm Merck has entered a new strategic collaboration with UK-based biopharmaceutical firm F-star to develop and commercialise five bispecific immuno-oncology antibodies.2017/7/18
-
Novartis and IBM Watson to optimise cancer care and patient outcomesNovartis has partnered with IBM Watson Health on an outcome-based initiative for patients with advanced breast cancer. The collaboration will involve research on a cognitive solution that uses real-w2017/7/17
-
Innate Pharma acquires anti-C5aR antibody from Novo NordiskFrench biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m. The m2017/7/17